Stay updated on Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    The study page now shows a 403 Forbidden message with a Home button, and the NIH transition announcement banner is no longer displayed.
    Difference
    2%
    Check dated 2026-11-09T14:53:09.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changed from v3.7.2 to v3.8.0, while the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T16:23:38.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    An NIH banner announces a website transition and says federal agencies are using “Super Intelligence” in place of “Artificial Intelligence” during the transition.
    Difference
    1%
    Check dated 2026-10-26T15:49:55.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    The footer revision label changed from v3.7.1 to v3.7.2 on the ClinicalTrials.gov error page.
    Difference
    0.2%
    Check dated 2026-10-19T16:46:38.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-12T16:51:09.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The study record page now displays a 403 error, replacing detailed study content and links with an error state; users are presented with a 403 page instead of the study details.
    Difference
    20%
    Check dated 2026-09-21T20:48:13.000Z thumbnail image

Stay in the know with updates to Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab-Chemo, Olaparib Maint in EOC Clinical Trial page.